VIC LINDEN: Open Payments
NPI 1073772141 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$999 in 57 payments from 11 companies in 2025. Trend: 2023 $1,038 · 2024 $806 · 2025 $999
Food & beverage: $999
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $243 |
| Lundbeck LLC | 12 | $219 |
| ABBVIE INC. | 5 | $105 |
| Axsome Therapeutics, Inc. | 4 | $96 |
| Supernus Pharmaceuticals, Inc. | 6 | $89 |
| Alkermes, Inc. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Janssen Pharmaceuticals, Inc | 1 | $29 |
| Bausch Health US, LLC | 1 | $29 |
Products named: REXULTI, CAPLYTA, VRAYLAR, Auvelity, Qelbree, ARISTADA, TRINTELLIX, SPRAVATO.
Industry payments across LA — which companies pay providers there.
